Positioned to transform the HBV treatment landscape and address the HBV global market opportunity
Portfolio of assets combining multiple technologies aimed at curing HBV
Proven scientific leadership in antiviral and RNAi drug discovery and development
Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus ("HBV") infection. We are advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).
Arbutus has a very broad HBV product pipeline against encompassing direct antiviral, host targeting and immune-based approaches, which include the following programs: RNAi, Capsid Inhibitor, HBV RNA Destabilizers and additional pre-clinical assets.
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
January 4 2021
December 10 2020
Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects
November 16 2020
